In silico evidence of bitopertin's broad interactions within the SLC6 transporter family.

This article investigates the pharmacological profile of bitopertin, a Glycine Transporter Type 1 (GlyT1, SLC6A9) inhibitor initially developed for schizophrenia treatment, using computational methods to explore its interactions within the Solute Carrier Family 6 (SLC6) neurotransmitter transporter family. Through target prediction, molecular modeling, docking, and molecular dynamics simulations, the study identifies bitopertin’s potential binding not only to GlyT1 but also to GlyT2 (SLC6A5), the proline transporter PROT (SLC6A7), and the dopamine transporter DAT (SLC6A3), indicating a broader, polypharmacological interaction profile. The findings suggest that bitopertin’s limited clinical efficacy may relate to its off-target interactions within the SLC6 family, highlighting the need for improved specificity in drug development. This comprehensive in silico analysis provides insights into bitopertin’s molecular mechanisms and supports further research into targeted therapies for neurological disorders.